Bone Total Current Liabilities from 2010 to 2024
| BBLGW Stock | USD 28.49 0.00 0.00% |
Total Current Liabilities | First Reported 2013-12-31 | Previous Quarter 284.5 K | Current Value 273.4 K | Quarterly Volatility 5.2 M |
Check Bone Biologics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bone Biologics' main balance sheet or income statement drivers, such as Other Operating Expenses of 9.9 M, Ebitda of 503.6 K or Total Operating Expenses of 4.7 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.43. Bone financial statements analysis is a perfect complement when working with Bone Biologics Valuation or Volatility modules.
Bone | Total Current Liabilities |
Latest Bone Biologics' Total Current Liabilities Growth Pattern
Below is the plot of the Total Current Liabilities of Bone Biologics Corp over the last few years. Total Current Liabilities is an item on Bone Biologics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Bone Biologics Corp are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. Bone Biologics' Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bone Biologics' overall financial position and show how it may be relating to other accounts over time.
| Total Current Liabilities | 10 Years Trend |
|
Total Current Liabilities |
| Timeline |
Bone Total Current Liabilities Regression Statistics
| Arithmetic Mean | 2,567,000 | |
| Geometric Mean | 357,347 | |
| Coefficient Of Variation | 154.88 | |
| Mean Deviation | 2,701,707 | |
| Median | 831,402 | |
| Standard Deviation | 3,975,747 | |
| Sample Variance | 15.8T | |
| Range | 13.7M | |
| R-Value | 0.23 | |
| Mean Square Error | 16.2T | |
| R-Squared | 0.05 | |
| Significance | 0.42 | |
| Slope | 200,653 | |
| Total Sum of Squares | 221.3T |
Bone Total Current Liabilities History
About Bone Biologics Financial Statements
Bone Biologics investors use historical fundamental indicators, such as Bone Biologics' Total Current Liabilities, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Bone Biologics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Current Liabilities | 831.4 K | 789.8 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Bone Stock Analysis
When running Bone Biologics' price analysis, check to measure Bone Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bone Biologics is operating at the current time. Most of Bone Biologics' value examination focuses on studying past and present price action to predict the probability of Bone Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bone Biologics' price. Additionally, you may evaluate how the addition of Bone Biologics to your portfolios can decrease your overall portfolio volatility.